{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "NCT00225095",
            "NStudiesAvail": 430269,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Determination of Quality of Life will be measured by the KOOS instrument (Knee injury and Osteoarthritis Outcome Score).",
                              "Patient perception of pain will be documented using a single VAS pain scale.",
                              "Lysholm knee score will be determined according to the questionnaire",
                              "Number of participants with Adverse Events.",
                              "Number of participants with clinically significant abnormalities in immunological measures",
                              "Number of participants with clinically significant abnormalities in laboratory assessments",
                              "Number of participants with clinically significant abnormalities in physical examinations.",
                              "Number of participants with clinically significant abnormalities in Magnetic Resonance Imaging (MRI)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Quality of Life Questionnaire",
                              "Visual Analog Scale (VAS)",
                              "Lysholm Knee Scale",
                              "Safety Assessment Adverse Event",
                              "Safety Assessment Immunological",
                              "Safety Assessment Laboratory",
                              "Safety Assessment Physical Exam",
                              "Safety Assessment Magnetic Resonance Imaging (MRI)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "2 years",
                              "Baseline to 2 years",
                              "2 years",
                              "2 years",
                              "2 years",
                              "2 years",
                              "2 years",
                              "2 years"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Osiris Therapeutics, Inc. Home Page"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.osiristx.com"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00225095"
                        ]
                  }
            ]
      }
}